Search

Your search keyword '"Kijima, Noriyuki"' showing total 167 results

Search Constraints

Start Over You searched for: Author "Kijima, Noriyuki" Remove constraint Author: "Kijima, Noriyuki" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
167 results on '"Kijima, Noriyuki"'

Search Results

2. Correction: Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort

3. CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy

4. Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort

5. Quantification of escape from X chromosome inactivation with single-cell omics data reveals heterogeneity across cell types and tissues

7. Subgroup and subtype-specific outcomes in adult medulloblastoma.

9. DOCK2 is involved in the host genetics and biology of severe COVID-19

10. A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases

13. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

14. Divergent clonal selection dominates medulloblastoma at recurrence

15. 10025-MPC-3 DIFFERENCE AMONG GENERATIONS IN PATIENTS WITH HISTONE H3-MUTATED GLIOMAS

16. 10053-MNG-1 STRATIFICATION OF TUMOR VOLUME GROWTH RATE USING RISK FACTORS IN SUPRATENTORIAL MENINGIOMAS

17. 10033-IM-2 IDENTIFICATION OF THERAPEUTIC TARGET ANTIGENS USING PATIENT DERIVED GLIOBLASTOMA AND THEIR APPLICATION TO CAR-T THERAPY

18. 10097-ACT-6 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPAN

19. 10184-BT-14 CLINICAL FEATURE OF HEMISPHERIC GLIOMA WITH H3F3A, PEDIATRIC-TYPE HIGH GRADE GLIOMA, H3 K27-ALTERED, NEC AND DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, CNS WHO GRADE 4

20. 10172-IM-6 DEVELOPMENT OF CAR-NK CELL THERAPY TARGETING B7H3 AGAINST GLIOBLASTOMA

22. 10179-NI-8 CLINICORADIOLOGICAL CHARACTERISTICS OF H3 K27-ALTERED THALAMIC GLIOMAS

23. 10157-BOT-1 DISCRIMINATION OF EPENDYMOMA AND MEDULLOBLASTOMA BY RAMAN SPECTROSCOPY

27. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma

29. ACT-20 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPAN

32. MPC-8 CLINICAL CHARACTERISTICS OF H3 K27-MUTATED GLIOMAS AT MIDLINE AND NEAR MIDLINE

34. MPC-15 CLINICAL FEATURE OF NON-MIDLINE GLIOMA WITH H3F3A GENE MUTATION

35. Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy

36. IMMU-19. IDENTIFICATION OF TARGET ANTIGENS FOR CHIMERIC ANTIGEN RECEPTOR T- CELL THERAPY AGAINST GLIOBLASTOMA USING A MONOCLONAL ANTIBODY LIBRARY RAISED AGAINST PATIENT-DERIVED TUMOR SPHERES

37. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

39. GCT-21. Long-term outcome and follow up of intracranial germ cell tumors: Reduced-dose radiotherapy and intensified chemotherapy improves clinical outcome and quality of life for long-term survivors

40. Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predicting MGMT promoter methylation and prognostic value in newly diagnosed patients with glioblastoma.

41. DOCK2 is involved in the host genetics and biology of severe COVID-19

42. TB-8 Genetic and molecular properties of long-term proliferating tumorsphere -forming glioma derived cells

47. TMOD-05. GENETIC AND MOLECULAR PROPERTIES OF LONG-TERM PROLIFERATING TUMORSPHERE -FORMING GLIOMA DERIVED CELLS

49. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy

50. Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas

Catalog

Books, media, physical & digital resources